Advocacy You Can Trust

Read more about the industries we’ve served, the clients we’ve helped, and the wins we’ve secured.

Industries Served

Our team serves clients across myriad industries, including those listed below. By not narrowing our practice to one or very few industries, we can better draw from diverse legal and factual scenarios to minimize jargon and tell your story plainly to judges and other audiences who may lack technical expertise.

  • Pharmaceuticals

  • Biosimilars

  • Antibodies

  • Polymers

  • Chemicals

  • Semiconductors

  • Robotics

  • Medical Devices

  • Refrigerants

  • Fracking

  • Telecommunications

  • Computer Networking

  • Video Displays

  • Video Games

Clients Served

Our team has proudly helped Fortune 500 and leading global brands solve their stickiest IP and legal problems in venues across the country.

  • Eli Lilly

  • Sanofi

  • Regeneron

  • Celltrion

  • Sandoz

  • Actavis

  • Abbott

  • Honeywell

  • Siemens

  • Sharp

  • Apple

  • Samsung

  • Sony

  • Cisco

  • iRobot

Selected Successes

  • BotM8 v. Sony (Fed. Cir.; 2021): Represented Sony on appeal in patent-infringement litigation over Playstation technologies. Federal Circuit ruled for Sony in its first-ever precedential opinion holding BotM8’s direct-infringement allegations were insufficient under Twombly/Iqbal.

  • INVT v. ITC (Fed. Cir.; 2021): Represented intervenors on appeal in patent-infringement litigation over wireless communication technologies. The Federal Circuit affirmed no violation and no domestic industry for an integral INVT patent.

  • Wi-LAN v. Sharp (D. Del.; 2021): Represented Sharp in patent-infringement litigation over system-on-a-chip technologies. The district court found the case exceptional and ordered Wi-LAN to pay Sharp’s attorneys’ fees.

  • Amgen v. Sanofi (Fed. Cir.; 2020-2021): Represented Sanofi and Regeneron on appeal in patent-infringement litigation over recombinant antibodies. The Federal Circuit affirmed the invalidity of Amgen’s patents in a landmark decision under § 112.

  • Oren Technologies v. Proppant Express (Fed. Cir.; 2020-2021): Represented Oren on appeal from an inter partes review over fracking technologies. The Federal Circuit ruled for Oren and reversed or vacated the PTAB’s invalidity findings for all challenged claims.

  • KIBP v. Samsung (Fed. Cir., E.D. Tex.; 2020): Represented Samsung in an appeal of a patent infringement case concerning FinFET transistors. Case settled favorably after Samsung filed its opening appellate brief.

  • iRobot v. SharkNinja (ITC, D. Mass., PTAB; 2019-2021): Represented iRobot in patent-infringement litigation over robotic floor cleaners. The ITC found Shark infringed and banned the infringing devices from the market.

  • BASF v. SNF (Fed. Cir.; 2019-2020): Represented BASF on appeal in patent-infringement litigation over superabsorbent polymers. The Federal Circuit reversed the district court on three separate grounds and vacated the invalidity of BASF’s patent while significantly clarifying the law on when confidential materials can be invalidating prior art.

  • Oyster v. Cisco (Fed. Cir.; 2019–2020): Represented Cisco on appeal in patent-infringement litigation over fiber optics technologies. The Federal Circuit affirmed that Oyster’s settlement in a related case released Cisco from patent liability.

  • Abbott v. Edwards (D. Del.; 2019-2020): Represented Abbott in patent-infringement litigation involving medical devices for treating cardiovascular disease. Case settled favorably before trial.

  • UCB v. Actavis (Fed. Cir.; 2018-2019): Represented Actavis on appeal in patent-infringement litigation over Parkinson’s treatments. The Federal Circuit affirmed the invalidity of one of UCB’s critical patents.

  • Janssen v. Celltrion (Fed. Cir.; 2017–2018): Represented Hospira and Celltrion in patent litigation over the first biosimilar monoclonal antibody approved by the FDA. The Federal Circuit affirmed Janssen’s patents were invalid for obviousness-type double patenting.

  • Allergan v. Sandoz (Fed. Cir.; 2017): Represented Sandoz in an appeal from a patent-infringement litigation over ocular hypertension medications. The Federal Circuit affirmed non-infringement for two patents and reversed infringement for a third patent, resulting in an outright non-infringement judgment for Sandoz.

  • Arkema v. Honeywell (Fed. Cir., PTAB; 2016–2020): Represented Honeywell in post-grant reviews of automobile-refrigerant patents and in related appeals. The Federal Circuit vacated and remanded the PTAB’s decision in Honeywell’s favor after the Board improperly refused to consider Honeywell’s certificate of correction.